Revenue and taxation; income tax credit; research institutes; effective date.
Summary
HB2087 revises Oklahoma’s income tax credit for donations to certain research institutions. The bill continues the existing credit for donations to independent biomedical research institutes and cancer research institutes, but changes how the credit is capped and calculated beginning in tax year 2026. It lowers the annual statewide credit cap for cancer research institute donations to $500,000 and sets the cap for independent biomedical research institute donations at $1.5 million, with the Oklahoma Tax Commission required to adjust the credit percentage each year so total claims stay within those limits.
The bill also changes taxpayer-level limits and eligibility definitions. For tax year 2026 and later, the credit for cancer research donations is limited to $1,000 for single filers and married filing separately, or $2,000 for joint filers, heads of household, and qualifying widows/widowers. For independent biomedical research donations, the same individual limits apply, while business entities may claim up to $25,000. The bill raises the NIH funding threshold for an independent biomedical research institute from $15 million to $20 million annually, and it keeps the requirement that a cancer research institute receive at least $4 million in National Cancer Institute funding each year. Unused credits may still be carried forward for four years, and the act becomes effective November 1, 2025.
Impact
HB2087 amends 68 O.S. 2021, Section 2357.45, which governs Oklahoma income tax credits for donations to qualifying biomedical and cancer research institutes. The bill changes the credit formula, annual aggregate caps, per-taxpayer limits, and the statutory definitions that determine which organizations qualify. It also directs the Oklahoma Tax Commission to administer the revised percentage-adjustment mechanism and continue issuing forms for the credit. The practical effect is to reduce and more tightly target the amount of tax credit available for these charitable donations beginning in tax year 2026, while preserving the credit structure for donors and eligible research organizations.
Sentiment
The bill appears to have broad support and moved through both chambers with strong margins. It passed the House Appropriations and Budget Committee unanimously, passed House third reading by a wide vote, and then passed the Senate Appropriations Committee unanimously as well. The available record shows no committee transcript or recorded debate, so there is little direct evidence of opposition in the materials provided. Overall, the voting history suggests a favorable view of the bill’s policy direction and its fiscal controls.
Contention
The main policy tension in HB2087 is between supporting research institutions through tax incentives and limiting the state’s exposure to foregone revenue. The bill reduces the total annual credit available for cancer research donations and sets separate caps for the two categories, which may concern donors or institutions that rely on larger credit availability. Another point of potential contention is the higher eligibility threshold for independent biomedical research institutes, which could narrow the number of organizations that qualify by requiring $20 million in annual NIH funding. No specific opposition arguments are documented in the provided materials, but the changes suggest a balancing of charitable incentives against budgetary restraint and tighter qualification standards.